Suh Chang-Hee, Kim Hyoun-Ah
Department of Allergy and Rheumatology, Ajou University School of Medicine, Woncheon-dong, San5, Youngtong-gu, Suwon, 443-721 South Korea.
Expert Rev Mol Diagn. 2008 Mar;8(2):189-98. doi: 10.1586/14737159.8.2.189.
Systemic lupus erythematosus is the most clinically diverse autoimmune disease. Owing to its heterogeneous presentation, clinical management of systemic lupus erythematosus remains as one of the greatest challenges. Therefore, there is a great need to assess disease activity accurately. Biomarkers can be objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention, and may also predict the risk of the disease, confirm diagnosis, monitor disease activity and provide prognostic information. Cytokines play an important and diverse role in the immune dysregulation in systemic lupus erythematosus. Measuring serum levels of soluble IL-2 receptor, IL-6, IL-10, soluble TNF receptor and IFN-alpha/IFN-induced genes may be promising biomarkers of disease activity in systemic lupus erythematosus.
系统性红斑狼疮是临床上最多样化的自身免疫性疾病。由于其临床表现具有异质性，系统性红斑狼疮的临床管理仍然是最大的挑战之一。因此，非常需要准确评估疾病活动度。生物标志物可以被客观地测量和评估，作为正常生物学过程、致病过程或对治疗干预的药理反应的指标，还可以预测疾病风险、确诊、监测疾病活动度并提供预后信息。细胞因子在系统性红斑狼疮的免疫失调中发挥着重要且多样的作用。测量血清中可溶性白细胞介素-2受体、白细胞介素-6、白细胞介素-10、可溶性肿瘤坏死因子受体以及干扰素-α/干扰素诱导基因的水平，可能是系统性红斑狼疮疾病活动度的有前景的生物标志物。
